Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical companies seeking precision medicine solutions,  announced a strategic partnership agreement to utilize Biofidelity’s Aspyre® Lung in global clinical trials.

Aspyre Lung simplifies the detection of established non-small cell lung cancer (NSCLC) biomarkers by analyzing both DNA and RNA from tissue and blood using a streamlined four-step workflow. Designed to run on existing qPCR platforms, it integrates seamlessly into laboratories globally and aligns with CellCarta’s mission to support global clinical trials through innovative genomic services.

Under the terms of the strategic partnership agreement, CellCarta will set up and validate Aspyre Lung in their European laboratories first, followed by its US-based laboratories and will have non-exclusive rights to utilize Aspyre Lung for clinical trials globally. The partnership provides customers with revolutionary services leveraging both liquid and tissue biopsy samples, helping accelerate and facilitate rapid and reliable clinical trial enrollment.

"We are extremely pleased to enter into this strategic partnership with CellCarta to expand the use of Aspyre Lung to global clinical trials," said Biofidelity Co-Founder and CEO Barnaby Balmforth, PhD. "At Biofidelity we’re actively working toward a future where more people around the world have access to the life-changing power of genomics. Partnering with CellCarta to make clinical trial enrollment faster and more efficient utilizing Simplified Genomic Profiling (SGP) via Aspyre Lung moves us significantly forward toward fulfilling our mission."

"We are excited to embark on this partnership with Biofidelity," said Dusty Tenney, CEO of CellCarta. "CellCarta offers an extensive portfolio of biomarker testing services and tailored solutions for the pharmaceutical and biotech industry. The addition of Aspyre Lung to our capabilities marks an advancement in our mission to propel precision medicine with specialized laboratory services."